In the PRATO-ACS trial , 504 consecutive statin-nave non-ST-elevation acute coronary syndrome patients scheduled for early invasive strategy and pretreated with high-dose clopidogrel were randomly assigned to rosuvastatin ( 40 mg on admission followed by 20 mg/d ; statin group , n = 252 ) or no statin treatment ( control group , n = 252 ) .